CMS Opens National Coverage Analysis For CAR-T Cell Therapies

May 17, 2018
CMS' Medicare Evidence Development & Coverage Advisory Committee will meet in August to consider a National Coverage Determination for chimeric antigen receptor (CAR)-T cell therapies after UnitedHealthcare requested such a determination to make sure there is a level playing field across Medicare for coverage of the expensive therapies. The agency says it expects to release a proposed decision memo next February and have the analysis completed by May 2019. “Given the complexity of the therapy, treating patients with acute life-threatening...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.